Table 1.
Baseline characteristics—Naïve population
| Naïve patients | Rheumatology cohort | Gastroenterology cohort | |||
|---|---|---|---|---|---|
| RA N = 77 |
PsA N = 48 |
AS N = 194 |
CD N = 208 |
UC N = 74 |
|
| Data capturing, n (%) | |||||
| Fully prospective | 66 (85.7%) | 39 (81.3%) | 170 (87.6%) | 189 (90.9%) | 67 (90.5%) |
| Shifted prospective | 7 (9.1%) | 2 (4.2%) | 7 (3.6%) | 6 (2.9%) | 1 (1.4%) |
| Fully retrospective | 4 (5.2%) | 7 (14.6%) | 17 (8.8%) | 13 (6.3%) | 6 (8.1%) |
| Age, years, mean (SD) | 54.4 (13.1) | 51.5 (12.3) | 44.9 (14.3) | 36.8 (14.0) | 37.1 (14.9) |
| Female patients, n (%) | 58 (75.3%) | 29 (60.4%) | 89 (45.9%) | 113 (54.3%) | 33 (44.6%) |
| Weight, kg, mean (SD) | 70.9 (13.9) | 79.1 (16.3) | 77.3 (17.0) | 67.3 (15.1) | 71.5 (14.5) |
| Height, cm, mean (SD) | 165.2 (8.6) | 169.0 (11.7) | 170.9 (8.9) | 170.1 (9.4) | 173.1 (8.8) |
| BMI, kg/m2, mean (SD) | 25.9 (4.9) | 27.7 (5.6) | 26.4 (5.5) | 23.2 (4.5) | 23.8 (4.1) |
| Disease duration, years, mean (SD) | 6.7 (6.8) | 5.5 (7.2) | 6.9 (9.0) | 7.9 (9.3) | 6.9 (8.2) |
| Patients with comorbidities at baseline, n (%)a | 26 (33.8%) | 26 (54.2%) | 83 (42.8%) | 74 (35.6%) | 24 (32.4%) |
| Patients with co-treatments at baseline, n (%)a | 65 (84.4%) | 28 (58.3%) | 35 (18.0%) | 108 (51.9%) | 54 (73.0%) |
| Prior exposure to other biologics, n (%) | |||||
| Infliximab | 1 (1.3%) | 1 (2.1%) | 16 (8.2%) | 33 (15.9%) | 4 (5.4%) |
| Etanercept | 13 (16.9%) | 10 (20.8%) | 31 (16.0%) | – | – |
| Ustekinumab | – | 3 (6.3%) | – | 8 (3.8%) | 1 (1.4%) |
| Vedolizumab | – | – | – | 7 (3.4%) | 2 (2.7%) |
| Golimumab | 2 (2.6%) | 1 (2.1%) | 19 (9.8%) | 1 (0.5%) | 2 (2.7%) |
| Certolizumab pegol | 5 (6.5%) | 2 (4.2%) | 10 (5.2%) | – | – |
| Abatacept | 4 (5.2%) | – | 1 (0.5%) | – | – |
| Tocilizumab | 5 (6.5%) | 1 (2.1%) | – | – | – |
| Rituximab | 1 (1.3%) | – | – | – | – |
| Secukinumab | – | 6 (12.5%) | 11 (5.7%) | – | – |
| Sarilumab | 1 (1.3%) | – | – | – | – |
| Ixekizumab | – | – | 2 (1.0%) | – | – |
| JAK inhibitors | 12 (15.6%) | – | 1 (0.5%) | – | 2 (2.7%) |
| Patients taking methotrexate at baseline, n (%) | 49 (63.6%) | 22 (45.8%) | 26 (13.4%) | 13 (6.3%) | 5 (6.8%) |
| Patients taking azathioprine at baseline, n (%) | – | – | – | 56 (26.9%) | 18 (24.3%) |
| Number of patients with disease activity scores at baseline, n (%) |
DAS28-ESR 23 (29.9%) DAS28-CRP 29 (37.7%) |
BASDAI 19 (39.6%) DAS28-ESR 14 (29.2%) DAS28-CRP 8 (16.7%) |
BASDAI 117 (60.3%) |
HBI 137 (65.9%) |
SCCAI 43 (58.1%) |
| Categorical disease activity scores, n (%) | |||||
| Remission | 1 (1.9%) | 5 (12.2%) | N/A | 83 (60.6%) | N/A |
| Low/mild disease activity | 5 (9.6%) | 4 (9.8%) | 23 (19.7%) | 33 (24.1%) | 19 (44.2%) |
| Moderate disease activity | 30 (57.7%) | 10 (24.4%) | N/A | 20 (14.6%) | N/A |
| High disease activity | 16 (30.8%) | 22 (53.7%) | 94 (80.3%) | 1 (0.7%) | 24 (55.8%) |
AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity index, CD Crohn’s disease, CRP C-reactive protein, DAS28 Disease Activity Score (28 joint), ESR erythrocyte sedimentation rate, HBI Harvey–Bradshaw index, N/A not applicable, PsA psoriatic arthritis, RA rheumatoid arthritis, SD standard deviation, SCCAI Simple Clinical Colitis Activity index, shifted prospective part prospective/part retrospective, UC ulcerative colitis
aFull listings of comorbidities and co-treatments reported at baseline are provided in Supplementary Tables S3A and S3B